Core Insights - GoodRx Holdings, Inc. is participating in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, to discuss business updates [1] - A live webcast of the conference will be available on the Company's Investor Relations website, with an archived recording accessible for at least 30 days post-conference [2] Company Overview - GoodRx is the leading platform for medication savings in the U.S., utilized by nearly 30 million consumers and over one million healthcare professionals annually [3] - The Company connects various stakeholders in the healthcare ecosystem, including consumers, healthcare professionals, payers, PBMs, pharmaceutical manufacturers, and retail pharmacies, to facilitate medication savings [3] - Since its inception in 2011, GoodRx has helped Americans save over $85 billion on medication costs [3]

Core Insights - GoodRx has announced the availability of Repatha® (evolocumab) at a significantly reduced cash price, making it more accessible to patients [1] - The new price for Repatha is set at $239, which represents a nearly 60% discount off the retail pharmacy list price [1] Company Overview - GoodRx is positioned as the leading platform for medication savings in the U.S., focusing on improving affordability in healthcare [1] Industry Impact - The introduction of a lower cash price for Repatha highlights the ongoing challenges of affordability in the healthcare system, where access is often dictated by cost [1]